Levy Y S, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D
Laboratory of Neurosciences, Felsenstein Medical Research Center and Department of Neurology, Rabin Medical Center, Beilinson Campus Tel Aviv University, Sackler School of Medicine, Petah-Tikva, Israel.
Cytotherapy. 2008;10(4):340-52. doi: 10.1080/14653240802021330.
Human bone marrow multipotent mesenchymal stromal cells (hMSC), because of their capacity of multipotency, may provide an unlimited cell source for cell replacement therapy. The purpose of this study was to assess the developmental potential of hMSC to replace the midbrain dopamine neurons selectively lost in Parkinson's disease.
Cells were isolated and characterized, then induced to differentiate toward the neural lineage. In vitro analysis of neural differentiation was achieved using various methods to evaluate the expression of neural and dopaminergic genes and proteins. Neural-induced cells were then transplanted into the striata of hemi-Parkinsonian rats; animals were tested for rotational behavior and, after killing, immunohistochemistry was performed.
Following differentiation, cells displayed neuronal morphology and were found to express neural genes and proteins. Furthermore, some of the cells exhibited gene and protein profiles typical of dopaminergic precursors. Finally, transplantation of neural-induced cells into the striatum of hemi-Parkinsonian rats resulted in improvement of their behavioral deficits, as determined by apomorphine-induced rotational behavior. The transplanted induced cells proved to be of superior benefit compared with the transplantation of naive hMSC. Immunohistochemical analysis of grafted brains revealed that abundant induced cells survived the grafts and some displayed dopaminergic traits.
Our results demonstrate that induced neural hMSC may serve as a new cell source for the treatment of neurodegenerative diseases and have potential for broad application. These results encourage further developments of the possible use of hMSC in the treatment of Parkinson's disease.
人骨髓多能间充质基质细胞(hMSC)因其多能性,可为细胞替代疗法提供无限的细胞来源。本研究的目的是评估hMSC替代帕金森病中选择性丢失的中脑多巴胺神经元的发育潜力。
分离并鉴定细胞,然后诱导其向神经谱系分化。使用各种方法对神经分化进行体外分析,以评估神经和多巴胺能基因及蛋白质的表达。然后将神经诱导细胞移植到半帕金森病大鼠的纹状体中;对动物进行旋转行为测试,处死动物后进行免疫组织化学分析。
分化后,细胞呈现神经元形态,并被发现表达神经基因和蛋白质。此外,一些细胞表现出多巴胺能前体典型的基因和蛋白质谱。最后,将神经诱导细胞移植到半帕金森病大鼠的纹状体中,可改善其行为缺陷,这通过阿扑吗啡诱导的旋转行为来确定。与未处理的hMSC移植相比,移植的诱导细胞显示出更大的益处。对移植脑的免疫组织化学分析表明,大量诱导细胞在移植后存活,一些细胞表现出多巴胺能特性。
我们的结果表明,诱导神经hMSC可能成为治疗神经退行性疾病的新细胞来源,并具有广泛的应用潜力。这些结果鼓励进一步探索hMSC在帕金森病治疗中的可能用途。